IE914034A1 - Tnf inhibitors - Google Patents

Tnf inhibitors

Info

Publication number
IE914034A1
IE914034A1 IE403491A IE403491A IE914034A1 IE 914034 A1 IE914034 A1 IE 914034A1 IE 403491 A IE403491 A IE 403491A IE 403491 A IE403491 A IE 403491A IE 914034 A1 IE914034 A1 IE 914034A1
Authority
IE
Ireland
Prior art keywords
tnf
xanthine
compound
formula
pharmaceutically acceptable
Prior art date
Application number
IE403491A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IE914034A1 publication Critical patent/IE914034A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IE403491A 1990-11-21 1991-11-20 Tnf inhibitors IE914034A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61647990A 1990-11-21 1990-11-21

Publications (1)

Publication Number Publication Date
IE914034A1 true IE914034A1 (en) 1992-06-03

Family

ID=24469639

Family Applications (1)

Application Number Title Priority Date Filing Date
IE403491A IE914034A1 (en) 1990-11-21 1991-11-20 Tnf inhibitors

Country Status (14)

Country Link
EP (1) EP0558659A4 (OSRAM)
JP (1) JP3204971B2 (OSRAM)
KR (1) KR930702896A (OSRAM)
AP (1) AP259A (OSRAM)
AU (1) AU656938B2 (OSRAM)
CA (1) CA2096623A1 (OSRAM)
HU (1) HUT65838A (OSRAM)
IE (1) IE914034A1 (OSRAM)
IL (1) IL100088A (OSRAM)
MX (1) MX9102173A (OSRAM)
NZ (1) NZ240644A (OSRAM)
TW (1) TW222001B (OSRAM)
WO (1) WO1992009203A1 (OSRAM)
ZA (1) ZA919178B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU7376394A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
AU2003289898A1 (en) * 2002-11-27 2004-06-18 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
RU2395511C2 (ru) * 2004-02-14 2010-07-27 Смитклайн Бичам Корпорейшн Новые соединения
PT1781657E (pt) 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
BR112017007194B1 (pt) 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd Compostos de hidroxil purina e uso dos mesmos
ES2784826T3 (es) 2015-10-29 2020-10-01 Guangdong Raynovent Biotech Co Ltd Forma cristalina de un compuesto de 4H-pirazol[1,5-]benzimidazol, procedimiento de preparación de la misma e intermediario de la misma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757328A (en) * 1903-02-07 1904-04-12 Boehringer & Soehne Art of preparing xanthin derivatives.
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.
DE2944568A1 (de) * 1979-11-05 1981-05-14 Institut für industrielle Pharmazie F + E GmbH, 8750 Aschaffenburg Pharmazeutische zubereitung
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
FI891419A7 (fi) * 1989-03-23 1990-09-24 Tampella Oy Ab Anordning i en gaengoeppningsanordning foer borrmaskineri.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
EP0558659A4 (en) 1993-10-20
IL100088A (en) 1995-07-31
EP0558659A1 (en) 1993-09-08
ZA919178B (en) 1992-10-28
CA2096623A1 (en) 1992-05-22
AP9100335A0 (en) 1992-01-31
HU9301509D0 (en) 1993-11-29
NZ240644A (en) 1994-08-26
HUT65838A (en) 1994-07-28
AU656938B2 (en) 1995-02-23
JPH06506192A (ja) 1994-07-14
AU9115991A (en) 1992-06-25
IL100088A0 (en) 1992-08-18
AP259A (en) 1993-06-03
WO1992009203A1 (en) 1992-06-11
KR930702896A (ko) 1993-11-29
TW222001B (OSRAM) 1994-04-01
MX9102173A (es) 1992-06-01
JP3204971B2 (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
US5420154A (en) TNF inhibitors
AP259A (en) Inhibitors for tumor necrosis factor (TNF) based 8-substituted xanthines.
US6207687B1 (en) Substituted imidazoles having cytokine inhibitory activity
CN100482664C (zh) 1,5-二取代-3,4-二氢-1H-嘧啶并[4,5-d]嘧啶二酮化合物和其在治疗CSBP/P38激酶介导的疾病中的用途
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
JPH11510156A (ja) キノロン類およびその医療上の使用
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
JP2003514900A (ja) ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
EP0572537B1 (en) Cytokine inhibitors
JP2003528043A (ja) ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
US5547979A (en) TNF inhibition
JP2023528722A (ja) サイトカインストーム症候群及び関連疾患を治療する方法
WO1993016699A1 (en) Tnf inhibitors
CN1260784A (zh) 作为pdeiv和tnf抑制剂的喹啉衍生物
WO2019225741A1 (ja) インドール化合物を含むネフローゼ症候群の治療又は予防剤
US20120190751A1 (en) Compounds for treatments of inflammation
EP1054669B1 (en) Use of thiadiazolo[4,3-a]pyridine derivatives
WO2004054616A1 (ja) ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
PT100429B (pt) Uso de derivados da xantina na preparacao de um medicamento para inibicao da producao de factor de necrose tumoral
KR20000035861A (ko) Ａｉｄｓ 치료용 약제를 제조하기 위한 ｐｋｃ 억제제의 사용 방법
US7858612B2 (en) Therapeutic agent for inflammatory bowel diseases
JPH10503178A (ja) Ｈｉｖ感染のための組合わせ療法
JPH0651622B2 (ja) インタロイキン‐１産生の阻止剤としての５―ヒドロキシおよび５―メトキシ２―アミノピリミジンの誘導体
CZ52199A3 (cs) Použití PKC inhibitorů pro výrobu léčiva pro léčbu nemocí centrálního nervového systému spojených s HIV infekcí
KR20000035863A (ko) Ｈｉｖ 감염과 관련된 중추 신경계 질환 치료용 약제를 제조하기 위해 ｐｋｃ의 억제제를 사용하는 방법

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)